2 gene-editing stocks reshaping hereditary disease treatments

Key PointsGene-editing is making headlines with the FDA approval of Casgevy, the first gene-editing treatment utilizing ex-vivo CRISPR/Cas9 for sickle cell disease (SCD), granted to Vertex Pharmaceuticals and CRISPR Therapeutics.Editas is focused on in-vivo treatment for SCD utilizing their EDIT-301 technology, which uses the proprietary enzyme CRISPR/Cas12 but also collects licensing fees for Cas9 from Vertex.Intellia’s co-founder, Jennifer Doudna, won the 2020 Nobel Prize for pioneering work in CRISPR tec ...